ECS04B
ATIA VISION AND THE OMNIVU MODULAR, SHAPE-CHANGING INTRAOCULAR LENS
D. Stephenson 1,2,*
1Stephenson Eye Associates, Venice, 2Atia Vision, Campbell, United States
Atia Vision, Inc., a Shifamed portfolio company, is committed to improving the visual outcomes of patients undergoing cataract surgery through the development of an intraocular lens that restores the full range of functional vision, minimizing visual disturbances. Building from the learnings in the accommodative IOL, we have created a novel presbyopia-correcting lens design called the OmniVu lens.
The OmniVu lens system is comprised of a fixed power front optic and a fluid-filled, shape-changing base lens. The fixed power front optic is made from hydrophobic acrylic and contains three docking tabs located equidistant around the periphery of the 5.6 mm optic. The shape-changing fluid-filled based shell is made from silicone and is filled with biocompatible silicone oil. The base contains an inner channel in which to dock the fixed power front optic.
The novel lens aims to restore a full range of vision, deliver binocular continuous focus across more than 4.0 D of defocus without visual symptoms and provide contrast sensitivity comparable to monofocal IOLs.
While the first-in-human clinical trial is ongoing, early review of results show promise. At 6 months, the OmniVu lens treated eyes showed stable refractive outcome with near plano refraction with no induced clinically significant astigmatism. The mean logMAR (±SD) monocular uncorrected VA was 0.04 (±0.09) at distance (6/6), 0.07 (±0.11) at intermediate (6/7.5), and 0.23 (±0.14) at near (6/9.5, J2). The mean (±SD) binocular uncorrected VA was -0.06 (±0.03) at distance (6/4.8), -0.02 (±0.09) at intermediate (6/6), and 0.17 (±0.09) at near (6/9.5, J2). Additional patients and follow-up are underway. Updated results will be presented.
The company is actively working toward US FDA submission for an IDE clinical trial.